Microneedle patch and manufacturing method thereof
By developing microneedle patches encapsulated by soluble polymers and lipid nanoparticles, the problem of unstable and difficult access to cells by nucleic acid drugs at room temperature is solved, efficient storage and distribution is achieved, the administration process is simplified, and the cells are improved Internalization efficiency.
Patent Information
- Application Number
- CN202410576721.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-12
- Filing Date
- 2024-05-10
- Publication Date
- 2024-11-12
AI Technical Summary
Nucleic acid drugs are unstable at room temperature and are difficult to enter cells, and existing delivery methods have problems of temperature sensitivity and difficulty in administration.
Develop a microneedle patch containing nucleic acid drugs encapsulated by soluble polymers and lipid nanoparticles. The microneedle is designed with a tip that penetrates the skin and is suitable for room temperature storage and by optimizing the lipid nanoparticle size and components, Improve the stability and cell internalization efficiency of nucleic acid drugs at room temperature.
It realizes efficient storage and distribution of nucleic acid drugs at room temperature, improves cell internalization efficiency, reduces drug costs, and simplifies the administration process.
Smart Images

Figure CN118924669A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a microneedle patch and a method for manufacturing the same. Specifically, the present invention relates to a microneedle patch for delivering nucleic acid drugs and a method for manufacturing the same. Background Art
[0002] Drugs are most commonly administered orally or by parenteral injection. Oral drug delivery is the most convenient and patient-friendly method of drug administration. However, first-pass elimination may reduce the bioavailability of orally ingested drugs. Subcutaneous injections can deliver drugs directly into the bloodstream, but professional assistance is required to administer the injection. To alleviate these issues, microneedle-mediated drug delivery systems can be utilized to self-administer therapeutic drugs virtually painlessly.
[0003] Dissolvable microneedles are polymer microneedles that encapsulate drugs within their matrix. When the dissolvable microneedles are inserted into the skin, the polymer compound begins to degrade, thereby releasing the drug for systemic or local delivery.
[0004] Nucleic acid drugs offer a new therapeutic modality with properties distinct from those of small molecules and antibodies. Nucleic acid drugs are the latest generation of drugs and have generated great interest from academia and industry. Because they have unique properties that allow them to access pharmacologically undruggable target proteins, they can be used to treat human diseases such as cancer, viral infections, and genetic disorders. Nucleic acid drugs can be designed without regard to the location or structure of the target molecule. Once the platform is established, drugs can be created by simply changing the nucleotide sequence of the target gene, allowing for rapid and efficient drug development. The success of the COVID-19 mRNA vaccine clearly demonstrates the potential of this class of drugs.
[0005] One problem with nucleic acid drugs is temperature sensitivity. Nucleic acids are relatively unstable at room temperature and have difficulty entering cells after administration. However, nucleic acids can be delivered intravenously, intramuscularly, subcutaneously, intradermally, and transdermally, making them very suitable for vaccination and treatment of some local diseases (e.g., skin diseases). Nucleic acid drugs are the latest version of drugs and have attracted great interest from academia and industry.
[0006] The present invention seeks to obviate or at least mitigate some of the above mentioned disadvantages of the prior art. Summary of the invention
[0007] In a first aspect, a microneedle patch is provided, comprising a substrate and a plurality of microneedles arranged on the substrate, wherein each of the plurality of microneedles comprises: (i) one or more polymers soluble in a human skin layer, (ii) a plurality of lipid nanoparticles and (iii) a nucleic acid drug encapsulated by the plurality of lipid nanoparticles; wherein each of the plurality of microneedles is defined with a tip portion capable of penetrating the skin, and wherein the microneedle patch is suitable for storage at room temperature (0-40°C).
[0008] Preferably, the nucleic acid drug is selected from the group consisting of plasmid DNA (pDNA), minicircle DNA (mcDNA), messenger RNA (mRNA), micro RNA (miRNA), antisense oligonucleotide (ASO), small interfering RNA (siRNA), aptamer and ribozyme.
[0009] Preferably, the plurality of lipid nanoparticles are formed of at least one component selected from the group consisting of: (4-hydroxybutyl) azanediyl bis(hexane-6,1-diyl) bis(2-hexyldecanoate), 1,2-di-O-octadecenyl-3-trimethylammonium-propane (DOTMA), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), dimethyldioctadecyl ammonium bromide (DDAB), 2,3-dioleyl-N-[2-(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propylammonium trifluoroacetate (DOSPA), ( 2S)-2,5-bis(3-aminopropylamino)-N-[2-(bisoctadecylamino)acetyl]pentanamide (DOGS; Transfectam), N1-[2-((1S)-1-[(3-aminopropyl)amino]-4-[bis(3-aminopropyl)amino]butylcarboxamido)ethyl]-3,4-di[oleyl]-benzamide (MVL5), DC-cholesterol 59, N4-cholesteryl-spermine (GL67), 4-(dimethylamino)butyric acid (6Z,9Z,28Z,31Z)-triacontane-6,9,28,31-tetraen-19-yl ester (DLin-MC3-DMA;MC3), 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioic acid di((Z)-non-2-en-1-yl) ester (L319), biodegradable lipid 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoic acid heptadecan-9-yl ester (lipid 5), 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoic acid heptadecan-9-yl ester (lipid H(SM-102))78 and ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315), 3,6-bis(4-(bis(2-hydroxydodecyl)amino)butyl)piperazine-2,5-dione (cKK-E12), (2-hexyldecanoate), 2-[(polyethylene glycol)-2000]-N,N-ditetradecyl acetamide, 1,2-di Myristoyl-rac-glyceryl-3-methoxypolyethylene glycol-2000 (PEG2000-DMG), 1,2-distearoyl-rac-glyceryl-3-methoxypolyethylene glycol-2000 (PEG2000-DSG), 1,2-distearoyl-sn-glyceryl-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG(2000)), 1 ,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), dipalmitoylphosphatidylcholine (DPPC), N-bis(2-hydroxyethyl)-N-methylethane-1-ammonium bromide (BHEM-cholesterol) and 3β-[N-(N′,N′-dimethylaminoethane)-carbamoyl]cholesterol (DC-cholesterol). ;
[0010] Preferably, the lipid nanoparticles are formed from an ionizable cationic lipid, polyethylene glycol (PEG), cholesterol and a helper lipid.
[0011] Preferably, the ionizable cationic lipid is 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP).
[0012] Preferably, the polyethylene glycol (PEG) is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy-(polyethylene glycol)-2000] (DSPE-PEG (2000)).
[0013] Preferably, the helper lipid is dipalmitoylphosphatidylcholine (DPPC).
[0014] Preferably, the size of the lipid nanoparticles is 50-220 nm or 100-150 nm.
[0015] Preferably, the size of the lipid nanoparticles is 120±30 nm with a size distribution (PDI) of less than 0.2.
[0016] Preferably, the one or more polymers are selected from the group comprising polyvinyl pyrrolidone, polyvinyl alcohol, hyaluronic acid, collagen, polyethylene glycol, their derivatives or mixtures thereof.
[0017] Preferably, the one or more polymers is a polymer mixture of polyvinyl pyrrolidone and polyvinyl alcohol.
[0018] Preferably, the ratio of polyvinyl pyrrolidone to polyvinyl alcohol is 0:100 to 100:0 (%).
[0019] Preferably, the molecular weight of the polyvinylpyrrolidone is 23,000-32,000 or 35,000-51,000 Daltons.
[0020] Preferably, the molecular weight of the polyvinyl alcohol is 72600-81400, 81400-94600 or 17600-26400 Daltons.
[0021] Preferably, the polymer mixture is further mixed with a sugar selected from the group consisting of sucrose, trehalose, dextrose and mixtures thereof to form another mixture, and wherein the concentration of the sugar in the another mixture is 0.1-10% (w / w).
[0022] Preferably, the nucleic acid drug is suitable for maintaining more than 50% of its original activity in a sealed centrifuge tube at room temperature (0-40°C) for at least 42 days, and maintaining biological activity for at least 60 days.
[0023] The nucleic acid drug is suitable for maintaining more than 50% of the original activity for at least 6 months at a storage temperature of 0-40°C and a humidity of about 40% or less.
[0024] In a second aspect, a method for manufacturing a microneedle patch is provided, comprising the following steps: (i) forming a plurality of nanoparticles in which a nucleic acid drug is encapsulated, (ii) mixing the plurality of nanoparticles with a polymer solution to form a matrix solution, wherein the polymer solution comprises one or more polymers soluble in a human skin layer, (iii) casting the matrix solution in a mold defining a plurality of grooves to produce a microneedle structure, wherein each of the microneedle structures defines a tip portion capable of penetrating the skin, (iv) drying the matrix solution to form a microneedle patch that can be stored at room temperature (0-40°C), and (v) removing the microneedle patch from the mold.
[0025] Preferably, the plurality of nanoparticles are formed by the following steps: (i) dissolving at least one lipid component in a first solvent and dissolving the nucleic acid in a second solvent, (ii) mixing the dissolved lipid component with the dissolved nucleic acid drug to form a drug mixture, (iii) passing the drug mixture through both an organic phase and an aqueous phase to form a nanosuspension, (iv) dialyzing the nanosuspension to remove the first and second solvents from the drug mixture, and (v) centrifuging the nanosuspension in a buffer solution to form the plurality of nanoparticles.
[0026] Preferably, the first solvent is ethanol.
[0027] Preferably, the second solvent is a sodium citrate buffer solution.
[0028] Preferably, the buffer solution is a phosphate buffered saline solution.
[0029] Preferably, the drug mixture passes through the organic phase and the aqueous phase at a flow rate of 1:3.
[0030] Preferably, the total flow rate of the drug mixture between the aqueous phase and the organic phase is 4-6 ml / min.
[0031] Preferably, the lipid concentration of the drug mixture is 3-14 mg / ml.
[0032] Preferably, the drug mixture passes through the organic phase and the aqueous phase in the microfluidic chip, and wherein the microfluidic chip is a Y-type or T-type microfluidic chip.
[0033] Preferably, dialysis of the nanosuspension is performed at low temperature for 24 to 48 hours, and preferably the low temperature is 4°C.
[0034] Preferably, the concentration of the polymer solution is 20-30%.
[0035] Preferably, the mold is treated with plasma before the matrix solution is cast into the mold.
[0036] Preferably, the method further comprises the step of packaging the microneedle patch in a nitrogen (N2) environment.
[0037] Preferably, the method further comprises the step of storing the microneedle patch at a temperature between 0-40°C and a humidity of about 40% or less.
[0038] Preferably, the method further comprises the step of storing the microneedle patch in a dry box at room temperature (0-40°C).
[0039] Preferably, the mold is a PDMS mold or a metal mold or a resin mold.
[0040] Preferably, the matrix solution is dried at a temperature between 25-30°C.
[0041] Preferably, the nucleic acid drug is selected from the group consisting of plasmid DNA (pDNA), minicircle DNA (mcDNA), messenger RNA (mRNA), micro RNA (miRNA), antisense oligonucleotide (ASO), small interfering RNA (siRNA), aptamer and ribozyme.
[0042] Preferably, the plurality of lipid nanoparticles are formed of at least one component selected from the group consisting of: (4-hydroxybutyl) azanediyl bis(hexane-6,1-diyl) bis(2-hexyldecanoate), 1,2-di-O-octadecenyl-3-trimethylammonium-propane (DOTMA), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), dimethyldioctadecyl ammonium bromide (DDAB), 2,3-dioleyl-N-[2-(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propylammonium trifluoroacetate (DOSPA), ( 2S)-2,5-bis(3-aminopropylamino)-N-[2-(bisoctadecylamino)acetyl]pentanamide (DOGS; Transfectam), N1-[2-((1S)-1-[(3-aminopropyl)amino]-4-[bis(3-aminopropyl)amino]butylcarboxamido)ethyl]-3,4-di[oleyl]-benzamide (MVL5), DC-cholesterol 59, N4-cholesteryl-spermine (GL67), 4-(dimethylamino)butyric acid (6Z,9Z,28Z,31Z)-triacontane-6,9,28,31-tetraen-19-yl ester (DLin-MC3-DMA;MC3), 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioic acid di((Z)-non-2-en-1-yl) ester (L319), biodegradable lipid 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoic acid heptadecan-9-yl ester (lipid 5), 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoic acid heptadecan-9-yl ester (lipid H(SM-102))78 and ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315), 3,6-bis(4-(bis(2-hydroxydodecyl)amino)butyl)piperazine-2,5-dione (cKK-E12), (2-hexyldecanoate), 2-[(polyethylene glycol)-2000]-N,N-ditetradecyl acetamide, 1,2-di Myristoyl-rac-glyceryl-3-methoxypolyethylene glycol-2000 (PEG2000-DMG), 1,2-distearoyl-rac-glyceryl-3-methoxypolyethylene glycol-2000 (PEG2000-DSG), 1,2-distearoyl-sn-glyceryl-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG(2000)), 1 ,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), dipalmitoylphosphatidylcholine (DPPC), N-bis(2-hydroxyethyl)-N-methylethane-1-ammonium bromide (BHEM-cholesterol) and 3β-[N-(N′,N′-dimethylaminoethane)-carbamoyl]cholesterol (DC-cholesterol). ;
[0043] Preferably, the lipid nanoparticles are formed from an ionizable cationic lipid, polyethylene glycol (PEG), cholesterol and a helper lipid.
[0044] Preferably, the ionizable cationic lipid is 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP).
[0045] Preferably, the polyethylene glycol (PEG) is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy-(polyethylene glycol)-2000] (DSPE-PEG (2000)).
[0046] Preferably, the helper lipid is dipalmitoylphosphatidylcholine (DPPC).
[0047] Preferably, the size of the lipid nanoparticles is 50-220 nm or 100-150 nm.
[0048] Preferably, the size of the lipid nanoparticles is 120±30 nm with a size distribution (PDI) of less than 0.2.
[0049] Preferably, the one or more polymers are selected from the group comprising polyvinyl pyrrolidone, polyvinyl alcohol, hyaluronic acid, collagen, polyethylene glycol, their derivatives or mixtures thereof.
[0050] Preferably, the one or more polymers is a polymer mixture of polyvinyl pyrrolidone and polyvinyl alcohol.
[0051] Preferably, the ratio of polyvinyl pyrrolidone to polyvinyl alcohol is 0:100 to 100:0 (%).
[0052] Preferably, the molecular weight of the polyvinylpyrrolidone is 23,000-32,000 or 35,000-51,000 Daltons.
[0053] Preferably, the molecular weight of the polyvinyl alcohol is 72600-81400, 81400-94600 or 17600-26400 Daltons.
[0054] Preferably, the method further comprises the step of mixing the polymer mixture with a sugar selected from the group consisting of sucrose, trehalose, dextrose and mixtures thereof to form another mixture, and wherein the concentration of the sugar in the another mixture is 0.1-10% (w / w).
[0055] Preferably, the nucleic acid drug is suitable for maintaining more than 50% of its original activity in a sealed centrifuge tube at room temperature (0-40°C) for at least 42 days, and maintaining biological activity for at least 60 days.
[0056] The nucleic acid drug is suitable for maintaining more than 50% of the original activity for at least 6 months at a storage temperature of 0-40°C and a humidity of about 40% or less. BRIEF DESCRIPTION OF THE DRAWINGS
[0057] In order to obtain a more accurate understanding of the above invention, the invention briefly described above will be described in more detail with reference to the specific embodiments illustrated in the accompanying drawings. The drawings presented herein may not be drawn to scale, and any reference to the dimensions in the drawings or the following description is specific to the disclosed embodiments.
[0058] Figure 1 a shows an embodiment of a method for manufacturing a microneedle patch according to the present invention;
[0059] Figure 1 b shows a fluorescence microscope image of the first embodiment of the microneedle patch (FITC-LNP-MN) of the present invention;
[0060] Figure 1 c shows Figure 1 b Photo of the microneedle patch;
[0061] Figure 1 d shows a photograph of a second embodiment of a microneedle patch (mRNA-LNP) according to the present invention;
[0062] Figure 2 a shows a cross-sectional view of a lipid nanoparticle according to an embodiment of the present invention, and the molecular formulas of the four components of the lipid nanoparticle within the microneedle patch;
[0063] Figure 2 b shows a photograph of FITC-dextran-LNP solution;
[0064] Figure 2 c illustrates the microfluidic process of forming multiple lipid nanoparticles encapsulating nucleic acid drugs;
[0065] Figure 3 A table of components for forming lipid nanoparticles is shown;
[0066] Figure 4 The optimization process of forming a microneedle patch by utilizing design of experiments (DOE) was demonstrated;
[0067] Figure 5 a and Figure 5 b shows a) response surface plot and b) two-dimensional (2D) contour plot of DOE for optimizing lipid nanoparticle size using total flow rate (TFR) and lipid concentration;
[0068] Figure 5 c and Figure 5 c) Response surface plot and d) 2D contour plot of DOE for optimization of lipid nanoparticle polydispersity index (PDI) using TFR and lipid concentration;
[0069] Figure 6 a is a graph showing the hydrodynamic diameters of mRNA-LNPs and FITC-dextran-LNPs;
[0070] Figure 6 b and Figure 6 c shows transmission electron microscopy (TEM) images of mRNA-LNP and FITC-dextran-LNP;
[0071] Figure 6 d shows the quantification and measurement of the hydrodynamic diameter and zero potential of mRNA-LNP and FITC-dextran-LNP;
[0072] Figures 7a to 7cShown are fluorescent images of mesenchymal stem cells (MSCs) transfected with a) enhanced green fluorescent protein (EGFP) mRNA alone, b) EGFP mRNA-lipofectamine, and c) EGFP mRNA-LNP;
[0073] Figure 7d Shown Figures 7a to 7c Quantification of the average fluorescence of each fluorescent cell in the fluorescence image;
[0074] Figure 7e to Figure 7g Flow cytometric analysis of MSCs transfected with e) EGFP mRNA alone, f) EGFP mRNA-lipofectamine, and g) EGFP mRNA-LNPs is shown;
[0075] Figure 7h Shows Figure 7e to Figure 7g Quantification of cell fluorescence intensity in flow cytometric analysis;
[0076] Figures 8a to 8c Fluorescence images of MSCs transfected with a) FITC-dextran alone, b) FITC-dextran-lipofectamine in microneedles, and c) FITC-dextran-LNP-MNs are shown;
[0077] Figure 8d Shown Figures 8a to 8c Quantification of the average fluorescence of each fluorescent cell in the fluorescence image;
[0078] Figure 8e to Figure 8g Flow cytometric analysis of MSCs transfected with e) FITC-dextran alone in MNs, f) FITC-dextran-lipofectamine in microneedles, and g) FITC-dextran-LNP-MNs is shown;
[0079] Figure 8h Shows Figure 8e to Figure 8g Quantification of cell fluorescence intensity in flow cytometric analysis;
[0080] Fig. 9 is a graph showing the relationship between the load force and the tip displacement of each patch of LNP-MN containing different concentrations (30%, 25%, 20%, 15%, 10%) of PVP under dry conditions at 20° C., 40° C., and 60° C.;
[0081] Fig.10 a to Fig.10 b shows a) response surface plot and b) 2D contour plot of DOE of polyvinylpyrrolidone (PVP) concentration and drying temperature on dispersibility.
[0082] Fig.10 c to Fig.10 d shows c) response surface plot and d) 2D contour plot of PVP concentration and drying temperature on Young's modulus;
[0083] Figures 11a to 11c Shown are fluorescent images of MSCs transfected with a) EGFP mRNA alone, b) EGFP mRNA-lipofectamine, and c) EGFP mRNA-LNP-MN;
[0084] Fig.11d Shown Figures 11a to 11c Quantification of the average fluorescence of each fluorescent cell in the fluorescence image;
[0085] Figure 11e to Figure 11g Flow cytometric analysis of MSCs transfected with e) EGFP mRNA alone, f) EGFP mRNA-lipofectamine, and g) EGFP mRNA-LNP-MNs is shown;
[0086] Fig.11h Shows Figure 11e to Figure 11g Quantification of cell fluorescence intensity in flow cytometric analysis;
[0087] Figures 11i to 11k Shows Figure 11e to Figure 11g Transfection results after 42 days of storage;
[0088] Figure 11l Shows Figures 11i to 11k Quantification of cell fluorescence intensity in flow cytometric analysis;
[0089] Figure 11m to Figure 11o Shows Figure 11e to Figure 11g Transfection results after 60 days of storage;
[0090] Figure 11p Shows Figure 11m to Figure 11o Quantification of cell fluorescence intensity in flow cytometric analysis;
[0091] Figures 12a to 12c Fluorescence images of MSCs transfected with a) FITC-dextran alone, b) FITC-dextran-lipofectamine in microneedles, and c) FITC-dextran-LNP-MNs are shown;
[0092] Fig.12d Shown Figures 12a to 12c Quantification of the average fluorescence of each fluorescent cell in the fluorescence image;
[0093] Figure 12e to Figure 12gFlow cytometric analysis of MSCs transfected with e) FITC-dextran alone in MNs, f) FITC-dextran-lipofectamine in microneedles, and g) FITC-dextran-LNP-MNs is shown;
[0094] Figure 12h Shows Figure 12e to Figure 12g Quantification of cell fluorescence intensity in flow cytometry;
[0095] Fig.13 a shows the fluorescence image of fibroblasts transfected with FITC-dextran-LNP-MN made with 25% PVP after drying at 60°C;
[0096] Fig.13 b shows the fluorescence image of fibroblasts transfected with FITC-dextran-LNP-MN made with 30% PVP after drying at 60 °C;
[0097] Fig.13 c shows a fluorescent image of fibroblasts transfected with FITC-dextran alone; and
[0098] Fig.14 a to Fig.14 c shows the fluorescence images of fibroblasts transfected with a) FITC-dextran alone, b) FITC-dextran-lipofectamine, and c) FITC-dextran-LNP;
[0099] Fig.14 d to Fig.14 f shows the fluorescence images of HEK 293 cells transfected with a) FITC-dextran alone, b) FITC-dextran-lipofectamine, and c) FITC-dextran-LNP;
[0100] Fig.15 a is a table showing the DOE data of lipid nanoparticles;
[0101] Fig.15 b is a table showing the DOE data of LNP-MN;
[0102] Fig.16a The intradermal delivery of mRNA to mice using an embodiment of a microneedle patch according to the present invention (ie, EGFP mRNA-LNP-MN) was demonstrated.
[0103] Fig.16b Shows accepted Fig.16a Heat map of mRNA intradermally delivered mice. DETAILED DESCRIPTION
[0104] 1. Overview of the Invention
[0105] Nucleic acid drugs are a class of DNA / RNA molecules that are believed to be able to treat protein-related diseases by regulating the expression of target proteins. A variety of nucleic acid drugs have been approved for the treatment of various diseases caused by gene defects, viral infections, and genetic mutations. The widespread use of mRNA vaccines in the COVID-19 epidemic has demonstrated the safety and great potential of these drugs.
[0106] The present invention describes a microneedle patch that can dissolve in the skin layer after penetrating the skin, which is used for intradermal delivery of nucleic acid drugs. The microneedle patch can be stored and distributed at room temperature (0-40°C). The microneedle patch of the present invention involves the development of lipid nanoparticles for encapsulating nucleic acid drugs, and the subsequent use of these lipid nanoparticles to make microneedles. The size and composition of the lipid nanoparticles are systematically optimized to maximize the stability of nucleic acids during storage at room temperature (0-40°C) and in a dry state. The microneedles are made of polymers and dissolve in the skin layer after penetrating the skin. The polymer also has little effect on the stability of nucleic acids.
[0107] Dissolvable microneedles are suitable for intradermal and transdermal delivery of nucleic acid drugs such as mRNA vaccines, DNA vaccines, and siRNA drugs. In one embodiment, the nucleic acid drug is selected from the group consisting of plasmid DNA (pDNA), microcircle DNA (mcDNA), messenger RNA (mRNA), microRNA (miRNA), antisense oligonucleotides (ASO), small interfering RNA (siRNA), aptamers, and ribozymes. Dissolvable microneedles can be stored and distributed at room temperature (0-40°C).
[0108] Dissolvable microneedles allow nucleic acids to be prepackaged in microneedle formulations that can be applied topically. Dissolvable microneedles also allow for rapid or rapid administration of drugs and mass vaccination as well as treatment of localized diseases. Additionally, lipid nanoparticles facilitate entry of nucleic acids into cells. Dissolvable microneedles can be stored and distributed at room temperature (0-40°C), which will reduce the overall cost of medication for patients, eliminating the challenges and costs associated with refrigeration and transportation.
[0109] The dissolvable microneedles form a patch having a base supporting the needle array, a substrate forming the base; and a drug. The drug is a nucleic acid drug. The dissolvable microneedles dissolve after penetrating the skin, and the dissolution duration is between about 1 second and about 10 minutes. During dissolution, at least a portion of the needles will be detached from the base. More preferably, the needles will dissolve regardless of the conditions selected from the group consisting of temperature, humidity, skin quality, age, gender and race.
[0110] In the present invention, the size of the lipid nanoparticles is controlled between 50-220nm or 100-150nm. The purified lipid nanoparticles are then mixed with an aqueous solution of polyvinyl pyrrolidone (PVP) and polyvinyl alcohol (PVA) and sugar. The size (molecular weight) of PVP can be 23000-32000 or 35000-51000 Daltons. The size (molecular weight) of PVA can be 72600-81400, 81400-94600 or 17600-26400 Daltons. The ratio of PVP to PVA ranges from 0:100 to 100:0 (%). Sugar can be sucrose or trehalose or dextrose or a mixture thereof. The sugar concentration in the PVP / PVA / sugar mixture is 0.1-10% (weight / weight).
[0111] 2. Fabrication of Dissolvable Microneedles
[0112] Reference now Figure 1 a, which shows an embodiment of a method 100 for preparing a microneedle patch 110 according to the present invention. Before forming the microneedle patch 110, it is necessary to prepare a microneedle mold 120. Preferably, the microneedle mold 120 is formed of polydimethylsiloxane (PDMS). In another embodiment, other biocompatible molding materials 140 such as certain types of metals and resins can also be used to form the microneedle mold 120.
[0113] Figure 1 a shows the use of a master mold 130 to create a microneedle mold 120 for making a microneedle patch 110. The master mold 130 has a needle-like structure pattern. A molding material 140 is poured onto the master mold 130 and solidified under vacuum to form a microneedle mold 120, which is a replica of the opposite side of the master mold 130, with a needle-like groove array. The surface of the microneedle mold 120 is then treated with plasma.
[0114] The purpose of plasma treatment on the surface of microneedle mold 120 is to enhance its hydrophilicity. Before plasma treatment, mold 120 is washed with deionized water and air-dried. A plasma treatment system can be used, which includes a generator with a 40kHz radio frequency signal. The mold 120 to be plasma activated is placed in a plasma chamber. A vacuum pump is used to reduce the pressure to 0.1mbar, and a process gas (i.e., oxygen with a purity of 99%) is sent to the plasma chamber in a pressure chamber. When this working pressure is reached, the generator is started, and the process gas in the receiver is ionized. The plasma treatment duration varies between 10, 20, 30, 40, 50 and 60 minutes.
[0115] To form the microneedle patch 110, two layers of aqueous solution are added to the microneedle mold 120 in a specific order. First, a mixture 150 of a plurality of lipid nanoparticle-encapsulated nucleic acids and a polymer solution mixed in a 1:1 ratio is added to fill the groove array of the microneedle mold 120. After filling the grooves, a second solution 160 consisting only of a polymer is added to the top of the first layer of solution 150 of the microneedle mold 120. The air gap between the two layers is eliminated by vacuuming. The gas is withdrawn and released three times in the vacuum chamber, each lasting 3 minutes, and the vacuum pressure applied is -1.0 bar. The microneedle mold 120 is then placed in a blast drying oven together with the two layers of solution 150 and 160, and dried at a temperature of about 20°C for 24 hours to shape the solution into a microneedle patch 110 having a substrate and a plurality of needle-like features arranged thereon. Due to the order in which the two solutions are added, only the microneedles contain nucleic acid drugs encapsulated in lipid nanoparticles, not the substrate. After cooling, the microneedles are removed from the mold 120.
[0116] The microneedle patch 110 is packaged in a nitrogen (N2) environment in a drying oven and a moisture-proof box, and stored in natural air at room temperature (0-40°C) and a humidity of about 40% or less, avoiding direct sunlight.
[0117] Figure 1 The fluorescence image in b shows the needle-like features 170 array FITC-LNP-MN of the microneedle patch 110, and Figure 1 c shows a photograph of the microneedle patch 110 .
[0118] Figure 1 d also shows a photograph of another embodiment of the microneedle patch 110, mRNA-LNP.
[0119] Lipid nanoparticles containing nucleic acids were fabricated using microfluidics (Y-type or T-type microfluidics), in which water and ethanol were used as solvents for drugs and lipids, respectively.
[0120] 3. Synthesis of lipid nanoparticles and encapsulation of nucleic acid drugs
[0121] Lipid nanoparticles (LNPs) are formed using microfluidics to encapsulate mRNA and small molecule drugs. Figure 2 a shows a cross section of a lipid nanoparticle. In one embodiment, the synthesis of lipid nanoparticles comprises four components, including (i) DOTAP chloride 201, a highly effective cationic lipid, (ii) dipalmitoylphosphatidylcholine (DPPC) 203, a phospholipid, (iii) 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy-(polyethylene glycol)-2000] (DSPE-PEG (2000)) 202 and cholesterol 204, as Figure 2 As shown in a.
[0122] Figure 2 c shows that the four components are dissolved in ethanol 220 at a molar ratio of 30:17.2:2.8:50. This mixture is then quickly combined with 52ug / ml EGFP-mRNA 240 dissolved in sodium citrate buffer (pH=4) 230 and 3mg / ml FITC-dextran 210 (model drug) dissolved in sodium citrate buffer 230 (pH=6). Figure 2 B shows a photograph of FITC-dextran solution 210 .
[0123] Nanosuspension is created by passing organic phase and aqueous phase mixture through microfluidic chip at a flow rate of 1:3. Then the obtained mRNA-LNP and FITC-LNP 250 nanosuspension are dialyzed to remove ethanol using a dialysis cup. Then, the centrifuge tube is filled with phosphate buffered saline (PBS) and rotated on a rotary shaker 260 for 18 hours in a dark environment, specifically for FITC-LNP. The PBS solution at the bottom is replaced every two hours. Finally, the dialyzed nanosuspension is transferred to a 2ml centrifuge tube.
[0124] Alternatively, lipid nanoparticles can also be used Figure 3The composition is formed by the components listed in, which include: (4-hydroxybutyl) azanediyl bis(hexane-6,1-diyl) bis(2-hexyldecanoate), 1,2-di-O-octadecenyl-3-trimethylammonium-propane (DOTMA), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), dimethyldioctadecyl ammonium bromide (DDAB), 2,3-dioleyl-N-[2-(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propylammonium trifluoroacetate (DOSPA), (2S)-2,5-dioleyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), dimethyldioctadecyl ammonium bromide (DDAB), 2,3-dioleyl-N-[2-(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propylammonium trifluoroacetate (DOSPA), (3-aminopropylamino)-N-[2-(dioctadecylamino)acetyl]pentanamide (DOGS; Transfectam), N1-[2-((1S)-1-[(3-aminopropyl)amino]-4-[di(3-aminopropyl)amino]butylcarboxamido)ethyl]-3,4-di[oleyl]-benzamide (MVL5), DC-cholesterol 59, N4-cholesteryl-spermine (GL67), 4-(dimethylamino)butyric acid (6Z,9Z,28Z,31Z)-triacontane-6,9,28,31-tetraen-19-yl ester (DLin-MC3-DMA;MC3), 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioic acid di((Z)-non-2-en-1-yl) ester (L319), biodegradable lipid 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoic acid heptadecan-9-yl ester (lipid 5), 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoic acid heptadecan-9-yl ester (lipid H(SM-102))78 and ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315), 3,6-bis(4-(bis(2-hydroxydodecyl)amino)butyl)piperazine-2,5-dione (cKK-E12), (2-hexyldecanoate), 2-[(polyethylene glycol)-2000]-N,N-ditetradecyl acetamide, 1,2-di Myristoyl-rac-glyceryl-3-methoxypolyethylene glycol-2000 (PEG2000-DMG), 1,2-distearoyl-rac-glyceryl-3-methoxypolyethylene glycol-2000 (PEG2000-DSG), 1,2-distearoyl-sn-glyceryl-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG(2000)), 1 ,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), dipalmitoylphosphatidylcholine (DPPC), N-bis(2-hydroxyethyl)-N-methylethane-1-ammonium bromide (BHEM-cholesterol) and 3β-[N-(N′,N′-dimethylaminoethane)-carbamoyl]cholesterol (DC-cholesterol). ;
[0125] 4. Optimization of LNP
[0126] Lipid nanoparticles (LNPs), including liposomes, solid lipid nanoparticles, nanostructured lipid carriers, and polymer-lipid hybrid nanoparticles, are an emerging type of drug carriers. Although the original idea came from liposomes (with a lipid bilayer structure), it has evolved into more complex structures with a wide range of physicochemical properties. But their roles in drug delivery are similar: enhancing solubility, stability, and bioavailability; reducing toxicity and side effects. Their success is documented by the approval of cancer drugs such as Doxil and COVID-19 mRNA vaccines by the U.S. Food and Drug Administration (FDA).
[0127] Transdermal delivery of these LNPs can be used for vaccination as well as treatment of local skin problems with less invasiveness and better patient compliance. Microneedles (MNs) are an emerging strategy to achieve transdermal delivery of LNPs in a minimally invasive manner. In this concept, LNPs are either embedded in a soluble MN matrix or coated on an insoluble MN surface. When MNs break through the stratum corneum and reach the epidermis and dermis, LNPs detach and diffuse through the skin to the subcutaneous tissue and capillaries.
[0128] To develop an effective and efficient LNP-MN delivery system, researchers must optimize the physicochemical properties of the LNPs that modulate nanobiointeractions (i.e., size and charge) and screen the MN materials and fabrication procedures to obtain adequate mechanical properties for the final device. Currently, optimization is accomplished through trial and error, which is heavily influenced by the individual experience and preferences of the researchers.
[0129] Design of Experiments (DOE), a systematic and efficient method for studying the relationship between multiple input and output variables, was used in the development of the present invention to optimize key process parameters in LNP-MN manufacturing, thereby breaking away from personal experience and preference. Figure 4 The optimization process of forming a microneedle patch by utilizing DOE is demonstrated. Specifically, the particle size of LNP and the formulation of MN are optimized by DOE. The resulting LNP-MN device can release 120nm LNP (PDI < 0.2) after dissolution, and can successfully transfect fibroblasts with organic dye molecules and EGFP-mRNA.
[0130] 4.1 Synthesis and optimization of LNPs using DOE method
[0131] LNPs composed of four lipid components were synthesized using a Y-type microfluidic device. These components included cationic lipids such as (2,3-dioleyloxy-propyl)-trimethylammonium chloride and (2,3-dioleyl-propyl)-trimethylamine (DOTAP), as well as 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG 2000), and cholesterol.
[0132] Fluorescein isothiocyanate-dextran (FITC-dextran, MW = 250,000Da) was used as a model drug for optimization. By changing the total lipid concentration and the total flow rate (TFR) between the aqueous phase and the organic phase, 2 2 The full factorial design adjusted the LNP size to between 125 and 190.4 nm (PDI ranged from 0.073 to 0.45), as Fig.15 As shown in the table in a.
[0133] During the experiment, the flow rate ratio (FRR) was fixed at 3, while the molar ratios of DOTAP, DPPC, DSPE-PEG 2000, and cholesterol were fixed at 30:18:2:50. The output variables were LNP size and PDI, while the input variables were lipid concentration and TFR. Figure 5 a and Figure 5 As shown in Figure 3, the correlation between factors and responses can be intuitively observed in the three-dimensional (3D) diagram of DOE.
[0134] The optimal size of LNPs is 120 ± 30 nm with a PDI less than 0.2 to ensure efficient cellular internalization. Figure 5 a shows the DOE response surface plot for LNP size optimization using TFR and lipid concentration. Predicted R 2 The value is 0.8891, which is consistent with the adjusted R 2 The value of 0.9668 is reasonably consistent (the difference is less than 0.2). 2 Is a statistic that measures the goodness of fit of the regression model to the observed data. It is a value between 0 and 1, with higher values indicating a better fit of the model to the data. Figure 5 a shows that LNP size decreases with increasing TFR regardless of the total lipid concentration value.
[0135] However, when the total lipid concentration was low, the LNP size changes due to changes in TFR were more significant. Figure 5 b shows contour lines indicating that the LNP size is approximately 120 ± 30 nm when TFR and lipid concentration are in the range of 8-4 ml / min and 24-3 mg / ml.
[0136] In addition, PDI was examined under different synthesis conditions (P value < 0.0001). PDI less than 0.2 in DLS measurement indicated that the size distribution of LNPs was uniform. Figure 5 c shows that PDI increases with increasing TFR regardless of lipid concentration. When the total lipid concentration is high, the change in PDI caused by changes in TFR is more significant.
[0137] There are two stages in the correlation between lipid concentration and PDI, such as Figure 5 c. At lower flow rates (TFR < 4.00 ml / min), the PDI decreases with increasing lipid concentration. This may be because higher lipid concentrations lead to better control of lipid self-assembly. When TFR is between 4-8 ml / min, higher lipid concentrations lead to larger PDI. This is because higher lipid concentrations may lead to a faster self-assembly process, resulting in a wider range of particle sizes, as not all particles have enough time to grow to the same size.
[0138] Figure 5 The contour plot in d shows that the PDI is greater than 2.0 only when TFR and lipid concentration are not distributed simultaneously in the ranges of 8-5 ml / min and 24-5 mg / ml. To ensure better control of the production process, TFR between 6-1 ml / min and total lipid concentration between 3-14 mg / ml were selected.
[0139] In summary, the optimal LNP formulation should have a narrow particle size distribution of 120 ± 30 nm (PDI < 0.2). This can be achieved by using a TFR of 4-6 ml / min and a lipid concentration range of 3-14 mg / ml.
[0140] 4.2 Synthesis and characterization of FITC-dextran-LNP or mRNA-LNP
[0141] FITC-dextran-LNP and mRNA-LNP were prepared using optimized total lipid concentration (6.5 mg / ml) and TFR (5.2 ml / min). The hydrodynamic diameter of both LNPs was approximately 140 nm (PDI, 0.18), which increased slightly to approximately 150 nm after dialysis. The zeta potentials of the LNPs were +10.1 mV and +13.6 mV, respectively. Figure 6 a and Figure 6 As shown in d.
[0142] Figure 6 b and Figure 6 c is a transmission electron microscope (TEM) image of mRNA-LNP and FITC-dextran-LNP, showing that FITC-dextran-LNP 620 and mRNA-LNP 610 both have a relatively uniform shape, with an outer double layer and an electron-dense inner amorphous structure. The drug percentage in LNP is also quantified. 1 mg FITC-dextran-LNP contains 0.3775 mg FITC-dextran, while 1 mg mRNA-LNP contains 0.02374 mg mRNA.
[0143] These LNPs were used to transfect mesenchymal stem cells (MSCs). The experiments included negative controls (FITC-dextran or mRNA (alone)), positive controls (molecules transfected using commercial Lipofectamine), and LNPs. The results of EGFP mRNA transfection were examined by fluorescence imaging, as shown in Figure 2. Figures 7a to 7c As shown. Both cells transfected with Lipofectamine 710 and LNP 720 showed fluorescence. Specifically, cells transfected with Lipofectamine showed a stronger average fluorescence per fluorescent cell, as shown in FIG. Figure 7d shown.
[0144] In contrast, negative control cells 730 showed no detectable EGFP fluorescence. These cells were further examined by flow cytometry analysis, as shown in Figure 7e to Figure 7g Interestingly, in the mRNA-LNP group, there were 99.4% EGFP-positive cells, while in the lipofectamine group this number was only 31.0%, as shown in Figure 2. Figure 7h shown.
[0145] for Figure 7d to Figure 7h , Values are expressed as mean ± SD. Error bars represent SD values from three independent experiments from three donors. Statistical differences are expressed as **p < 0.005, ***p < 0.001.
[0146] The difference between fluorescence quantification and flow analysis suggests that LNPs provide more uniform transfection, whereas lipofectamine can carry more molecules into certain parts of the cell. This can be Figure 7e to Figure 7h This is confirmed by the traffic data. Figure 7f In the lipofectamine group, the distribution of cells with different fluorescence intensities was Figure 7g (LNP group) is more extensive.
[0147] Referring now to FIG8 , lipofectamine and LNP show completely different results when FITC-dextran is used as the molecule to be delivered. Figures 8a to 8c Fluorescence images and Figure 8e to Figure 8g In the flow cytometry analysis of lipofectamine 810, FITC-dextran was not carried into the cells. In contrast, LNP 820 successfully transfected the cells with FITC-dextran.
[0148] Similar to mRNA transfection, Figure 8g The transfection shown is also uniform. The failure of using liposome 810 to carry out FITC-dextran transfection can be explained by the zeta potential of FITC-dextran-lipofectamine conjugate. In mRNA transfection, EGFP-mRNA-lipofectamine 820 shows the zeta potential of+6.310mV in DMEM, which will allow compounding between cell membrane and EGFP-mRNA-lipofectamine conjugate. However, FITC-dextran-lipofectamine conjugate 810 shows negative zeta potential in DMEM, which will be unfavorable for compounding.
[0149] for Figure 8d to Figure 8h , Values are expressed as mean ± SD. Error bars represent SD values from three independent experiments from three donors. Statistical differences are expressed as **p < 0.005, ***p < 0.001.
[0150] Fibroblasts and HEK 293 were successfully transfected using FITC-dextran-LNP. Fig.14 a to Fig.14 c shows the fluorescence images of fibroblasts transfected with a) FITC-dextran alone, b) FITC-dextran-lipofectamine, and c) FITC-dextran-LNP. Lipofectamine 1410 did not bring FITC-dextran into the fibroblasts because Fig.14 No fluorescence is shown in b. In contrast, LNP 1420 successfully transfected fibroblasts with FITC-dextran.
[0151] Fig.14 d to Fig.14 f shows fluorescent images of HEK 293 cells transfected with a) FITC-dextran alone, b) FITC-dextran-lipofectamine, and c) FITC-dextran-LNP. Similarly, Lipofectamine 1430 did not carry FITC-dextran into HEK 293 cells because Fig.14 In e, fluorescence is not shown, but LNP 1440 successfully transfected HEK 293 cells with FITC-dextran.
[0152] 4.3 Fabrication and optimization of soluble LNP-MN formulations using DOE approach
[0153] LNP-MNs were fabricated by a template fusion method, in which a solution containing polymer and mRNA-LNP or FITC-dextran LNP was loaded into a negative MN mold and then dried. The concentration of polymer (PVP) and drying temperature were key parameters in this process.
[0154] The mechanical strength of the soluble MN was tested using a tensile testing machine. Fig. 9 Graph showing the relationship between the loading force and the tip displacement for each patch of LNP-MN containing different concentrations (30%, 25%, 20%, 15%, 10%) of PVP under dry conditions at 20°C, 40°C and 60°C.
[0155] The output variables, the so-called responses, are the Young's modulus of the LNP-MNs and the size of the LNPs after dissolution of the LNP-MNs. The Young's modulus is obtained from the force-displacement curve of the compression test, as Fig. 9 Young's modulus is a mechanical property of solid materials that measures the tensile or compressive stiffness when subjected to a longitudinal force. The correlation between the factors and the response is shown in the 3D plot of the DOE, as shown in Fig.10 The PVP concentration was adjusted between 100-30%, and the drying temperature was in the range of 20°C to 60°C.
[0156] Fig.10 a is the response surface diagram of the size of LNPs released at different PVP concentrations (10-30%) and drying temperatures (20°C, 40°C, 60°C). Ideal LNP-MNs should have a higher Young's modulus, and the LNPs released from LNP-MNs have the same hydrodynamic diameter (150nm) as the unencapsulated LNPs. At all drying temperatures, higher PVP concentrations are beneficial to maintaining particle size. This should be due to the higher PVP concentration, the higher the viscosity of the solution, which prevents the aggregation of nanoparticles. From the contour lines ( Fig.10 b) It can be seen that when the PVP concentration and drying temperature are 24-30% and 22-60°C, respectively, the size of the dissolved LNPs is less than 180 nm.
[0157] In addition to the dispersibility of LNP-MNP, the study also examined the effect of different fabrication conditions on the Young's modulus properties of the microneedle material. Fig.10 c and 10d, the mechanical properties of MNPs are significantly affected by PVP concentration and drying temperature. When the PVP concentration is between 10% and 30%, the Young's modulus of the microneedles increases with the increase in drying temperature. When the temperature is between 20°C and 60°C, the mechanical properties of the microneedles increase with the increase in PVP concentration. Since mRNA is easily degraded at high temperatures, we tried to dry mRNA-LNPs at lower temperatures. Therefore, we tried to obtain LNP-MNPs with higher Young's modulus at lower drying temperatures.
[0158] At a 30% PVP concentration and a temperature of 25°C, the force of each microneedle patch (100 tips) can be as high as 190,000N / m2. The compressive strength of the soluble MN loaded with PVP of LNP is 19MPa. This exceeds the force required for normal skin penetration (0.058N). In addition, a concentration of 30% PVP and a drying temperature of 25°C can meet the requirement that the dissolved LNP size is less than 180nm.
[0159] 4.4 LNP-MN Released LNPs and Cell Transfection in Vitro
[0160] The optimized LNP-MNs were used to transfect mesenchymal stem cells (MSCs). Negative controls (FITC-dextran or mRNA (only)) and positive controls (using commercial Lipofectamine) were also included. The results of EGFP mRNA-LNP-MN transfection were checked by fluorescence imaging, as shown in Figures 11a to 11c shown.
[0161] Cells transfected with both Lipofectamine 1110 and LNP-MN 1120 showed fluorescence. The fluorescence intensity of LNP-MN1120 was comparable to that of cells transfected with Lipofectamine 1110. This indicates that the microneedle manufacturing and drying process does not damage the mRNA-LNP.
[0162] Flow cytometric analysis ( Fig.11e -h) shows that the transfection efficiency of LNP-MN is over 40%, which is much higher than that of the positive control group (8.51%) and more uniform than that of lipopolysaccharide transfection.
[0163] In contrast, negative control cells showed no detectable EGFP fluorescence, as Fig.11d shown.
[0164] These cells were further examined by flow cytometric analysis, e.g. Figure 11e to Figure 11g As shown in Figure 4. Similar results were obtained in the LNP transfection group. This shows that LNP-MN provides a more uniform transfection. Figure 11i-11l As shown, the prepared mRNA-LNP-MN patch was stored in a sealed container for 42 days before transfection of mesenchymal stem cells, wherein the storage temperature was set at 23°C and the humidity range was 50%-63%.
[0165] In particular Fig.11h The transfection of the mRNA-LNP-MN group used directly after production is shown, with an average value of EGFP positivity (%) of 43.3%. In contrast, the transfection results of the same group after 42 days showed an average value of EGFP positivity of 22.633%. The results show that mRNA-LNP-MNs still maintain more than 50% of the original transfection efficiency after 42 days.
[0166] Figure 11m-11o illustrate Figures 11e-11g Store transfection results after 60 days; Figure 11p show Figure 11m-11o Quantification of cell fluorescence intensity in flow cytometric analysis. Figure 11p As shown, after 60 days of storage, the transfection results of the mRNA-LNP-MN group showed that the average value of eGFP-positive cells was 3.14%. The transfection results after 60 days were still significantly higher than those of mRNA transfection alone, thus proving the biological activity of the drug after 60 days.
[0167] Referring to FIG. 12 , when FITC-dextran was delivered via LNP-MN, only LNP-MN 1220 brought FITC-dextran into cells, while lipofectamine 1210 did not, as shown in FIG. Figures 12a to 12c Fluorescence images and Figure 12e to Figure 12gAs shown in the flow cytometry analysis, the transfection efficiency of FITC-dextran-LNP-MN was very high, exceeding 95%, which proved that the LNP in the soluble microneedles could be well taken up by cells.
[0168] for Figure 11d to Figure 11h and Figure 12d to Figure 12h , Values are expressed as mean ± SD. Error bars represent SD values from three independent experiments from three donors. Statistical differences are expressed as **p < 0.005, ***p < 0.001.
[0169] like Fig.13 As shown, fibroblasts were also successfully transduced using FITC-dextran-LNP-MNs manufactured at a high drying temperature of 60 °C.
[0170] Fig.13 a shows the fluorescence image of fibroblasts transfected with FITC-dextran-LNP-MN made with 30% PVP after drying at 60 °C; Fig.13 b shows the fluorescence image of fibroblasts transfected with FITC-dextran-LNP-MN made with 30% PVP after drying at 60 °C; Fig.13 c shows the fluorescent image of fibroblasts transfected with FITC-dextran alone.
[0171] It can be seen Fig.13 a and Fig.13 The presence of fluorescence in b indicates that the LNPs are stable during the MN drying process.
[0172] This indicates that the soluble LNP-MN delivery system has great potential in delivering nucleic acids, proteins, and small molecules through DOE optimization process. The LNP-MNP process parameters can be designed according to the structure, physicochemical properties, and required storage conditions of the drug to optimize the efficiency of microneedle vaccine delivery.
[0173] 5. Discussion
[0174] The present invention constructs an advanced soluble LNP-MN patch. Through the DOE method, the problems of long test cycle and high test cost, as well as rough test methods and ineffective evaluation of the interaction between inputs can be avoided. The large-scale design and manufacture of MN is of great significance to meet the market demand for personalized medicine.
[0175] The relationship between the influencing factors and their interactions in LNP microfluidic manufacturing is also being studied. In the large-scale synthesis of LNP, the flow rate should be controlled as much as possible, otherwise too high a flow rate will not only fail to reduce the particle size of LNP, but also make it difficult to achieve continuous and stable LNP synthesis, resulting in large batch-to-batch errors.
[0176] At the same time, the manufacturing research of microneedles also aims to optimize their mechanical properties and dispersion properties. In addition, the effects of different materials such as PVA, sucrose, maltose, etc. on the performance of microneedles can be compared, and the storage and transportation conditions, as well as the damage of nucleic acids and other drugs during high-temperature manufacturing, can be considered.
[0177] 6. Materials and Methods
[0178] 6.1 Synthesis of lipid nanoparticles
[0179] LNPs were prepared by microfluidic technology and can be used to encapsulate mRNA and small molecule drugs. Microfluidic devices were used to select highly efficient cationic lipid DOTAP chloride, phospholipid dipalmitoylphosphatidylcholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy-(polyethylene glycol)-2000] (DSPE-PEG(2000)) and cholesterol to synthesize lipid nanoparticles. China) synthesized lipid nanoparticles.
[0180] The four materials were dissolved in ethanol at a molar ratio of 30:17.2:2.8:50, and were quickly combined with sodium citrate buffer (pH=4) dissolving 52ug / ml egfp-mRNA (Dakewe) and sodium citrate buffer (pH=6) dissolving 3mg / ml FITC-dextran (Sigma-Aldrich). The nanosuspension was obtained by passing through a microfluidic chip at a flow rate of 1:3 between the organic phase and the aqueous phase. The obtained mRNA-LNP and FITC-LNP nanosuspensions were dialyzed from ethanol in a dialysis cup. The centrifuge tube was filled with phosphate buffered saline and rotated on a rotary shaker for 18 hours, taking care to avoid light. The PBS solution at the bottom was replaced every two hours, and the dialyzed nanosuspension was finally transferred to a 2ml centrifuge tube.
[0181] 6.2 Characterization of the physicochemical properties of LNPs
[0182] The sample liposomes synthesized by microfluidics were characterized. The LNPs were analyzed by dynamic light scattering (DLS). The particle size was measured by DLS, and the PDI of the LNPs was analyzed, and the LNPs were diluted with phosphate buffered saline (PBS) and added to a high concentration cell equipped with a transparent electrode to measure the zeta potential. The three measurements for each sample were averaged.
[0183] 6.3 Transmission Electron Microscopy (TEM)
[0184] TEM photography of mRNA-LNP and FITC-dextran-LNP. Lipid nanoparticles were loaded on a special copper plate and then imaged using a transmission electron microscope. TEM provides high-resolution images that reveal the morphology and diameter of the LNP.
[0185] 6.4 LNP encapsulation efficiency
[0186] As previously described, the RNA assay kit was used to determine the percentage of encapsulated RNA and RNA concentration. To quantify the amount of unencapsulated RNA in LNPs, samples were diluted to an expected total RNA concentration of 10 μg / mL in 1× TE buffer before adding RiboGreen dye. To quantify the total amount of RNA, samples were diluted to an expected total RNA concentration of 10 μg / mL in 1× TE buffer containing 0.5% (vol / vol) Triton X-100 before adding the dye. Standard solutions were prepared in 1× TE containing 0.5% (vol / vol) Triton X-100 with a final RNA concentration of 0-2.5 μg / mL. The assay was performed according to the manufacturer's protocol. Fluorescence intensity was measured at excitation at 480 nm and emission at 520 nm. The transfection dose was based on the calculated encapsulation dose.
[0187]
[0188] For FITC-LNP, by the method similar to the above, because FITC-dextran fluorescence intensity varies with its concentration.By dissolving FITC-dextran of different concentrations with PBS buffer, the standard curve of fluorescence intensity and FITC-dextran concentration was drawn.The plate was read by a microplate reader to obtain the FITC-LNP fluorescence intensity in the dialyzed sample, and the concentration can be obtained by calculation.
[0189] 6.5 Optimization of LNP
[0190] A three-factor, two-level 24-full factorial design was used to examine the main effects and interactions of different treatment and formulation parameters and to determine the optimal formulation parameters for FITC-LNP. The factors examined were A: total flow rate (affecting Re number) B: DOTAP concentration C: DOTAP-DSPE-PEG (2000) ratio (weight / weight) response factors (i.e., critical mass attributes: particle size, polydispersity index (PDI), and zeta potential). The levels of each variable are represented as -1, 0, and +1. The exact test conditions are listed in Table 1. The experiment was performed 18 times with a center point of 2×2 3 +2 times.
[0191] 6.6 Loading mRNA-LNP and FITC-LNP into MNs
[0192] Fabrication of dissolving microneedles
[0193] First, MN molds were prepared and each was subjected to plasma treatment (30S) to enhance its hydrophilicity. The oxygen plasma treatment was washed with deionized water and air-dried before plasma treatment. This study used a plasma treatment system that used a generator with a 40kHz radio frequency signal. The molded sample to be plasma activated was placed in a plasma chamber. The pressure was reduced to 0.1mbar using a vacuum pump, and the process gas (i.e., oxygen with a purity of 99%) was fed into the plasma chamber in this pressure chamber. When this working pressure was reached, the generator was started and the process gas in the receiver was ionized. The plasma treatment time varied between 10, 20, 30, 40, 50, and 60 minutes.
[0194] The mRNA-LNP and FITC-LNP and polymer (PVP) solution were mixed in a 1:1 ratio and poured into the previously prepared MN mold. The air gap was eliminated by vacuuming. The mold was then dried in an oven and the MN was taken out after cooling.
[0195] 6.7 Optimization of soluble microneedle performance
[0196] The performance of the microneedles was also optimized using a DOE experimental design. The factors studied were A: PVP concentration B: oven drying temperature response factor (i.e., critical mass attribute): mechanical properties of the microneedles, and the polydispersity index (PDI) of the dissolved LNPs. The levels of each variable are represented as -1, 0, +1. The exact test conditions are shown in Table 1. The experiment was performed 9 times with a center point of 2×2 2 +1 times, where PDI is only used as a reference value to observe the dispersion of LNP after microneedle dissolution and compare the storage effects of different preparations. For example, glucose, sucrose, mannitol, etc. However, sugars are susceptible to moisture and are not easy to store and transport.
[0197] 6.8 Transfection experiments of mRNA-LNP and FITC-LNP
[0198] Test whether different cells can take up FITC-LNP. HEK-293 cells, MSCs and fibroblasts were cultured in DMEM medium containing 10% FBS at 37°C in a humidified atmosphere containing 5% CO2 (for HEK-293K and fibroblasts). Cells were seeded in 6-well plates (30w / well) and 350ul of dialyzed FITC-LNP nanosuspension was added. A control group was also set up, and 4ug / ml mRNA and 3mg / ml FITC-dextran were added to the cells. Positive control group: 6ul Lipofectamine 3000 was combined with 4ug / ml EGFP-mRNA and mixed.
[0199] Each well was diluted to 1.5 ml / well with DMEM containing 1% FBS and incubated in an incubator for 8 hours. After transfection, the mixture was removed, aspirated, and washed 3 times with PBS buffer. Replaced with DMEM containing 10% FBS and incubated for 24-48 hours.
[0200] 6.9 Endocytosis test
[0201] The steps are the same as conventional transfection, and control experiments are set up during transfection. The first group of control HEK293 cells were transfected according to the above procedure, and the second group was transfected in the following manner: placed in a 4°C refrigerator for 40 minutes, then taken out, washed with PBS and replaced with DMEM 1% FBS medium without FITC-LNP, and incubated at 37°C for 10 minutes. After removing the medium, it was replaced with DMEM (1% FBS) mixed with 500ul and 250ul of FITC-LNP, and returned to 4°C, and removed after 40min. The first group of cells was taken out at the same time, the two groups of cells were washed three times with PBS, and DMEM (10% FBS) was replaced with DMEM to observe the fluorescence intensity of the two groups of cells under a fluorescence microscope and analyze the endocytosis of LNP by the cells.
[0202] 6.10 Soluble microneedle transfection test.
[0203] Take out the prepared FITC-dextran-LNP-loaded MNPs and take pictures under a fluorescence microscope to observe whether FITC-dextran-LNPs are present at the bottom of the needle tip. MNPs are dissolved in DMEM (1% FBS) and transfected into MSCs for 4-8 hours. Then, DMEM is converted to 10% FBS and cells are expressed for 48 hours. Fluorescence intensity is observed under a fluorescence microscope.
[0204] 6.11 Evaluation of transfection efficiency by fluorescence microscopy
[0205] To measure EGFP expression in adherent MSCs, cells were imaged 48 h after transfection using a Nikon fluorescence microscope with an excitation light source of 488 nm. The fluorescence intensity of the microscopic images was analyzed using Image-J.
[0206] 6.12 Measurement of cell transfection efficiency by flow cytometry
[0207] After 24-48 hours of expression post-transfection, cells were collected for further washing with PBS and analyzed by flow cytometry. After a washing step using flow cytometry washing solution, transfected MSC cells were collected by pipetting the collected cells. All flow cytometry data were analyzed using FlowJo software V10.
[0208] 6.13 Statistical analysis
[0209] All data were analyzed using GraphPad Prism version 9.0 (GraphPad Software Inc.) and expressed as mean ± standard error of the mean (SEM). One-way or two-way analysis of variance (ANOVA) was used to test differences between groups. Specific statistical analysis methods are described in the legends showing the results. For p < 0.05, values were considered statistically significant.
[0210] 7. More Information
[0211] Fig.16a The process of delivering mRNA intradermally to mice using an embodiment of a microneedle patch according to the present invention is shown 1600. After in vitro optimization of mRNA transfection 1610, an ideal microneedle patch is formed. Such a microneedle patch is manufactured and applied to mice at room temperature (0-40°C) 1620. When the microneedle patch is applied to the skin of the mouse, the microneedles release mRNA intradermally in vivo 1630. Fig.16b Shown are the results of process 1600 for intradermal delivery of mRNA to mice at 0 h, 12 h, and 24 h.
[0212] The exemplary embodiments have been fully described so far. Although the description refers to specific embodiments, it should be clear to those skilled in the art that the present invention can be practiced by variations in these specific details. Therefore, the present invention should not be construed as being limited to the embodiments set forth herein.
[0213] Although the embodiments have been illustrated and described in detail in the above description, they should be considered as illustrative rather than restrictive, and it should be understood that only exemplary embodiments are shown and described, and the scope of the present invention is not limited in any way. It is understood that any feature described herein can be used in any embodiment. The exemplary embodiments do not mutually exclude or exclude other embodiments not described herein. Therefore, the present invention also provides an embodiment including a combination of one or more exemplary embodiments described above. Without departing from the spirit and scope of the present invention, the present invention as set forth herein can be modified and varied, and therefore, only the limitations indicated by the appended claims should be applied.
Claims
1. A microneedle patch comprising a substrate and a plurality of microneedles disposed on the substrate, wherein each of the plurality of microneedles comprises: (i) one or more polymers that are soluble in the human skin layer, (ii) multiple lipid nanoparticles and (iii) a nucleic acid drug encapsulated by the plurality of lipid nanoparticles; Each of the plurality of microneedles defines a tip portion capable of penetrating skin, and wherein the microneedle patch is suitable for storage at room temperature.
2. The microneedle patch according to claim 1, wherein the nucleic acid drug is selected from the group consisting of plasmid DNA (pDNA), minicircle DNA (mcDNA), messenger RNA (mRNA), micro RNA (miRNA), antisense oligonucleotide (ASO), small interfering RNA (siRNA), aptamer and ribozyme.
3. The microneedle patch according to claim 1, wherein the plurality of lipid nanoparticles are formed of at least one component selected from the group consisting of: (4-hydroxybutyl) azanediyl bis(hexane-6,1-diyl) bis(2-hexyldecanoate), 1,2-di-O-octadecenyl-3-trimethylammonium-propane (DOTMA), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), dimethyldioctadecyl ammonium bromide (DDAB), 2,3-dioleyl-N-[2-(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propylammonium trifluoroacetate (DOSPA), (2S)-2,5-bis(3-aminopropylamino)-N-[2-(bisoctadecylamino)acetyl]pentanamide (DOGS; Transfectam), N1-[2-((1S)-1-[(3-aminopropyl)amino]-4-[bis(3-aminopropyl)amino]butylcarboxamido)ethyl]-3,4-di[oleyl]-benzamide (MVL5), DC-cholesterol 59, N4-cholesteryl-spermine (GL67), 4-(dimethylamino)butyric acid (6Z,9Z,28Z,31Z)-triacontane-6,9,28,31-tetraen-19-yl ester (DLin-MC3-DMA;MC3), 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioic acid di((Z)-non-2-en-1-yl) ester (L319), biodegradable lipid 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoic acid heptadecan-9-yl ester (lipid 5), 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoic acid heptadecan-9-yl ester (lipid H(SM-102))78 and ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315), 3,6-bis(4-(bis(2-hydroxydodecyl)amino)butyl)piperazine-2,5-dione (cKK-E12), (2-hexyldecanoate), 2-[(polyethylene glycol)-2000]-N,N-ditetradecyl acetamide, 1,2-di Myristoyl-rac-glyceryl-3-methoxypolyethylene glycol-2000 (PEG2000-DMG), 1,2-distearoyl-rac-glyceryl-3-methoxypolyethylene glycol-2000 (PEG2000-DSG), 1,2-distearoyl-sn-glyceryl-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG(2000)), 1 ,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), dipalmitoylphosphatidylcholine (DPPC), N-bis(2-hydroxyethyl)-N-methylethane-1-ammonium bromide (BHEM-cholesterol) and 3β-[N-(N′,N′-dimethylaminoethane)-carbamoyl]cholesterol (DC-cholesterol). ; 4. The microneedle patch according to claim 1, wherein the lipid nanoparticles are formed of ionizable cationic lipids, polyethylene glycol (PEG), cholesterol and helper lipids.
5. The microneedle patch of claim 4, wherein the ionizable cationic lipid is 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP). 6 . The microneedle patch according to claim 4 , wherein the polyethylene glycol (PEG) is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy-(polyethylene glycol)-2000] (DSPE-PEG (2000)).
7. The microneedle patch of claim 4, wherein the helper lipid is dipalmitoylphosphatidylcholine (DPPC).
8. The microneedle patch according to claim 1, wherein the size of the lipid nanoparticles is 50-220 nm or 100-150 nm.
9. The microneedle patch according to claim 1, wherein the size of the lipid nanoparticles is 120±30 nm and the size distribution (PDI) is less than 0.
2.
10. The microneedle patch of claim 1, wherein the one or more polymers are selected from the group comprising polyvinyl pyrrolidone, polyvinyl alcohol, hyaluronic acid, collagen, polyethylene glycol, derivatives thereof, or mixtures thereof.
11. The microneedle patch of claim 1, wherein the one or more polymers is a polymer mixture of polyvinyl pyrrolidone and polyvinyl alcohol. 12 . The microneedle patch according to claim 11 , wherein the ratio of the polyvinyl pyrrolidone to the polyvinyl alcohol is 0:100 to 100:0 (%).
13. The microneedle patch according to claim 11, wherein the molecular weight of the polyvinyl pyrrolidone is 23000-32000 or 35000-51000 Daltons.
14. The microneedle patch of claim 11, wherein the molecular weight of the polyvinyl alcohol is 72600-81400, 81400-94600 or 17600-26400 Daltons.
15. The microneedle patch of claim 11, wherein the polymer mixture is further mixed with a sugar selected from the group consisting of sucrose, trehalose, dextrose, and mixtures thereof to form another mixture, and wherein the concentration of the sugar in the another mixture is 0.1-10% (w / w).
16. The microneedle patch of claim 1, wherein the nucleic acid drug is suitable for maintaining more than 50% of its original activity in a sealed centrifuge tube at room temperature for at least 42 days and maintaining biological activity for at least 60 days.
17. A method for manufacturing a microneedle patch, comprising the following steps: (i) forming a plurality of nanoparticles in which a nucleic acid drug is encapsulated, (ii) mixing the plurality of nanoparticles with a polymer solution to form a matrix solution, wherein the polymer solution comprises one or more polymers that are soluble in a layer of human skin, (iii) casting the matrix solution in a mold defining a plurality of grooves to produce a microneedle structure, wherein each of the microneedle structures defines a tip portion capable of penetrating the skin, (iv) drying the matrix solution to form a microneedle patch that can be stored at room temperature, and (v) removing the microneedle patch from the mold.
18. The method of claim 17, wherein the plurality of nanoparticles are formed by: (i) dissolving at least one lipid component in a first solvent and dissolving the nucleic acid drug in a second solvent, (ii) mixing the dissolved lipid component with the dissolved nucleic acid drug to form a drug mixture, (iii) passing the drug mixture through both an organic phase and an aqueous phase to form a nanosuspension, (iv) dialyzing the nanosuspension to remove the first and second solvents from the drug mixture, and (v) centrifuging the nanosuspension in a buffer solution to form the plurality of nanoparticles.
19. The method of claim 18, wherein the first solvent is ethanol.
20. The method of claim 18, wherein the second solvent is a sodium citrate buffer solution.
21. The method of claim 18, wherein the buffer solution is a phosphate buffered saline solution.
22. The method of claim 18, wherein the drug mixture passes through the organic phase and the aqueous phase at a flow rate of 1:
3.
23. The method of claim 18, wherein the total flow rate of the drug mixture between the aqueous phase and the organic phase is 4-6 ml / min.
24. The method of claim 18, wherein the lipid concentration of the drug mixture is 3-14 mg / ml.
25. The method according to claim 18, wherein the drug mixture passes through the organic phase and the aqueous phase in a microfluidic chip, and wherein the microfluidic chip is a Y-type or T-type microfluidic chip.
26. The method of claim 18, wherein the dialysis of the nanosuspension is performed at low temperature for 24 to 48 hours.
27. The method of claim 26, wherein the low temperature is 4°C.
28. The method of claim 17, wherein the concentration of the polymer solution is 20-30%.
29. The method of claim 17, wherein the mold is treated with plasma prior to casting the matrix solution into the mold.
30. The method according to claim 17, further comprising the step of packaging the microneedle patch in a nitrogen (N2) environment.
31. The method of claim 17, further comprising the step of storing the microneedle patch at a temperature between 0-40°C and a humidity of about 40% or less.
32. The method of claim 17, further comprising the step of storing the microneedle patch in a dry box at room temperature.
33. The method according to claim 17, wherein the mold is a PDMS mold, a metal mold or a resin mold.
34. The method of claim 17, wherein the nucleic acid drug is selected from the group consisting of plasmid DNA (pDNA), minicircle DNA (mcDNA), messenger RNA (mRNA), micro RNA (miRNA), antisense oligonucleotides (ASO), small interfering RNA (siRNA), aptamers, and ribozymes.
35. The method of claim 17, wherein the plurality of lipid nanoparticles are formed from at least one component selected from the group consisting of: (4-hydroxybutyl) azanediyl bis(hexane-6,1-diyl) bis(2-hexyldecanoate), 1,2-di-O-octadecenyl-3-trimethylammonium-propane (DOTMA), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), dimethyldioctadecyl ammonium bromide (DDAB), 2,3-dioleyl-N-[2-(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propylammonium trifluoroacetate (DOSPA), (2S)-2,5-bis(3-aminopropylamino)-N-[2-(bisoctadecylamino)acetyl]pentanamide (DOGS; Transfectam), N1-[2-((1S)-1-[(3-aminopropyl)amino]-4-[bis(3-aminopropyl)amino]butylcarboxamido)ethyl]-3,4-di[oleyl]-benzamide (MVL5), DC-cholesterol 59, N4-cholesteryl-spermine (GL67), 4-(dimethylamino)butyric acid (6Z,9Z,28Z,31Z)-triacontane-6,9,28,31-tetraen-19-yl ester (DLin-MC3-DMA;MC3), 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioic acid di((Z)-non-2-en-1-yl) ester (L319), biodegradable lipid 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoic acid heptadecan-9-yl ester (lipid 5), 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoic acid heptadecan-9-yl ester (lipid H(SM-102))78 and ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315), 3,6-bis(4-(bis(2-hydroxydodecyl)amino)butyl)piperazine-2,5-dione (cKK-E12), (2-hexyldecanoate), 2-[(polyethylene glycol)-2000]-N,N-ditetradecyl acetamide, 1,2-di Myristoyl-rac-glyceryl-3-methoxypolyethylene glycol-2000 (PEG2000-DMG), 1,2-distearoyl-rac-glyceryl-3-methoxypolyethylene glycol-2000 (PEG2000-DSG), 1,2-distearoyl-sn-glyceryl-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG(2000)), 1 ,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), dipalmitoylphosphatidylcholine (DPPC), N-bis(2-hydroxyethyl)-N-methylethane-1-ammonium bromide (BHEM-cholesterol) and 3β-[N-(N′,N′-dimethylaminoethane)-carbamoyl]cholesterol (DC-cholesterol). ; 36. The method of claim 17, wherein the lipid nanoparticles are formed from an ionizable cationic lipid, polyethylene glycol (PEG), cholesterol, and a helper lipid.
37. The method of claim 36, wherein the ionizable cationic lipid is 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP).
38. The method of claim 36, wherein the polyethylene glycol (PEG) is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy-(polyethylene glycol)-2000] (DSPE-PEG (2000)).
39. The method of claim 36, wherein the helper lipid is dipalmitoylphosphatidylcholine (DPPC).
40. The method of claim 17, wherein the size of the lipid nanoparticles is 50-220 nm or 100-150 nm.
41. The method of claim 17, wherein the lipid nanoparticles have a size of 120 ± 30 nm and a size distribution (PDI) of less than 0.
2.
42. The method of claim 17, wherein the one or more polymers are selected from the group comprising polyvinyl pyrrolidone, polyvinyl alcohol, hyaluronic acid, collagen, polyethylene glycol, derivatives thereof, or mixtures thereof.
43. The method of claim 17, wherein the one or more polymers is a polymer mixture of polyvinyl pyrrolidone and polyvinyl alcohol.
44. The method according to claim 17, wherein the ratio of the polyvinyl pyrrolidone to the polyvinyl alcohol is 0:100 to 100:0 (%).
45. The method of claim 17, wherein the molecular weight of the polyvinyl pyrrolidone is 23,000-32,000 or 35,000-51,000 Daltons.
46. The method of claim 17, wherein the molecular weight of the polyvinyl alcohol is 72600-81400, 81400-94600, or 17600-26400 Daltons.
47. The method of claim 17, further comprising the step of mixing the polymer mixture with a sugar selected from the group consisting of sucrose, trehalose, dextrose, and mixtures thereof to form another mixture, and wherein the concentration of the sugar in the another mixture is 0.1-10% (w / w).
48. The method of claim 17, wherein the nucleic acid drug is suitable for maintaining more than 50% of its original activity in a sealed centrifuge tube at room temperature for at least 42 days, and maintaining biological activity for at least 60 days.
Citation Information
Cited By
Microneedle patch
TWI930934B
